What is ATRA's P/E ratio?

Atara Biotherapeutics Inc (ATRA) currently trades at a P/E ratio of 32.27.

Atara Biotherapeutics Inc reports a Return on Equity (ROE) of 25.37%.

What is ATRA's dividend yield?

Atara Biotherapeutics Inc offers a dividend yield of 0.00%.

What is ATRA's Quality Score?

Our AI rates ATRA's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy ATRA?

Our AI Timing Score for ATRA is 30 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does ATRA belong to?

Atara Biotherapeutics Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Atara Biotherapeutics Inc (ATRA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

ATRA AI Analysis Summary

Our AI summary for ATRA: Atara Biotherapeutics Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 32.27, ROE of 25.37%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 30/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

ATRA

Atara Biotherapeutics Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 87

USD 8.77

0.22 (2.57%) Day Change

Watchlist Portfolio Compare Chart

32.27

P/E

-0.03

D/E

25.4%

ROE

-47.3%

ROA

0.00%

Div Yield

-0.51

PEG

ATARA BIOTHERAPEUTICS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 8.77 Price 0.22 (2.57%) Day Change	NEWS SCORE: 87

ATRA, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...

Loading chart...

38 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	87
Magic Formula Rank by ROA	850
Magic Formula Rank by ROE	850
Magic Formula Rank by ROIC	824
Price	8.77
PBV / Sector	-2.06 / 44,022.72
Earning Per Share	-1.08

PE / Sector	32.27 / 19.17
PEG or PE/Growth / Sector	-0.51 / 1.24
Average 1M Daily Value	0.65 M GREAT
Average 1W Daily Value	0.44 M GREAT

Timing Factors

57%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

37%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

56%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-40.91 / 98.24
NPM Average (%) / Sector	-732.02 / -1,697.63
NPM Change Average (%) / Sector	76.73 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-47.34 / 185,260.96
ROA Average (%) / Sector	-38.31 / 36,684.70
ROA Change Average (%) / Sector	-78.42 / 422,221.66
ROE (%) / Sector	25.37 / 243,762.23 GOOD
ROE Average (%) / Sector	25.25 / 48,758.47 GREAT
ROE Change Average (%) / Sector	-162.35 / 424,968.10
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 07:59:51
Symbol	ATRA
Name	ATARA BIOTHERAPEUTICS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	9.01 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	77.04 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 1280 Rancho Conejo Blvd, Thousand Oaks, CA, United States, 91320

Phone: 805 623 4211

Website: https://www.atarabio.com

Sector: Healthcare >> Biotechnology

Description: Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and internationally. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. It also develops ATA3219, an allogeneic CAR T targeting CD19 intended to target B-cell malignancies and autoimmune diseases. The company has research collaboration agreements with Memorial Sloan Kettering Cancer Center, and Council of the Queensland Institute of Medical Research. Atara Biotherapeutics, Inc. was incorporated in 2012 and is headquartered in Thousand Oaks, California.